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Objectives This study was designed to investigate the clinical course of women with long QT syndrome (LQTS) throughout
their potential childbearing years.
Background Only limited data exist regarding the risks associated with pregnancy in women with LQTS.
Methods The risk of experiencing an adverse cardiac event, including syncope, aborted cardiac arrest, and sudden death,
during and after pregnancy was analyzed for women who had their first birth from 1980 to 2003 (n 391). Time-
dependent Kaplan-Meier and Cox proportional hazard methods were used to evaluate the risk of cardiac events dur-
ing different peripartum periods.
Results Compared with a time period before a woman’s first conception, the pregnancy time was associated with a reduced
risk of cardiac events (hazard ratio [HR] 0.28, 95% confidence interval [CI] 0.10 to 0.76, p 0.01), whereas the
9-month postpartum time had an increased risk (HR 2.7, 95% CI 1.8 to 4.3, p 0.001). After the 9-month postpar-
tum period, the risk was similar to the period before the first conception (HR 0.91, 95% CI 0.55 to 1.5, p 0.70).
Genotype analysis (n  153) showed that women with the LQT2 genotype were more likely to experience a cardiac
event than women with the LQT1 or LQT3 genotype. The cardiac event risk during the high-risk postpartum period
was reduced among women using beta-blocker therapy (HR 0.34, 95% CI 0.14 to 0.84, p 0.02).
Conclusions Women with LQTS have a reduced risk for cardiac events during pregnancy, but an increased risk during the
9-month postpartum period, especially among women with the LQT2 genotype. Beta-blockers were associated
with a reduction in cardiac events during the high-risk postpartum time period. (J Am Coll Cardiol 2007;49:
1092–8) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.054h
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Mhe hereditary long QT syndrome (LQTS) is characterized
y prolonged ventricular repolarization and a variable clin-
cal course with arrhythmia-related recurrent syncope,
borted cardiac arrest (ACA), and sudden death (1). Mu-
ations in several ion-channel genes are known to cause
QTS, the most common of which are found in potassium-
hannel KCNQ1 (LQT1) and hERG (LQT2) genes, and
n the sodium-channel SCN5A (LQT3) gene (2).
enotype-phenotype studies have highlighted the clinical
ourse in the 3 major LQTS subgroups (3). However, there
rom the *Cardiology Division of the Department of Medicine and the †Depart-
ent of Pathology, University of Rochester Medical Center, Rochester, New
ork; ‡Departments of Medicine, Pediatrics, and Molecular Pharmacology,
ayo Clinic College of Medicine, Rochester, Minnesota; §Department of
ardiology, Bikur Cholim Hospital, Jerusalem, Israel; The Heart and
ascular Research Center, MetroHealth Campus, Case Western Reserve Univer-ity, Cleveland, Ohio; ¶Cardiovascular Department De Gasperis, Niguarda
ospital, Milan, Italy; Molecular Cardiology, Fondazione S. Maugeri and the 2ave been only 3 studies evaluating the risks of pregnancy in
atients with LQTS (4–6), with the report by Khositseth et
l. (5) identifying the LQT2 genotype as a risk factor for
ostpartum cardiac events in a small number of women. The
resent study was designed to investigate the clinical course
f LQTS in women throughout the childbearing years with
comparison with those who did and did not experience
regnancy, with additional focus on the risk associated with
ifferent LQTS genotypes and the prophylactic effectiveness
f beta-blocker therapy during and after pregnancy.
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tudy population. The enrollment of subjects with LQTS
nto the International LQTS Registry has been previously
escribed (1,7). A baseline electrocardiogram (ECG) was
btained on all subjects enrolled in the registry. The QT
nterval was measured in lead II of the ECG and corrected for
eart rate according to the method of Bazett (QTc  QT/
RR). Yearly follow-up information, with particular empha-
is on cardiac events, was obtained for each subject. All subjects
r their guardians provided informed consent for acquisition of
he clinical data and the genetic studies.
The study population consisted of women of childbearing
ge from the registry who were identified as having an
QTS-related gene mutation or were considered to be
ffected with LQTS on the basis of a QTc 470 ms. The
tudy subjects who were born between July 1946 and March
985 (n  1,094) were categorized as of May 2003 as either
aving 1 or more live births (n  564) or as being
ulliparous (n  520). The live-birth category contained
omen who gave birth before 1980 (n  173) and from
980 to March 2003 (n  391). This chronological subdi-
ision was used because beta-blocker therapy was fully
vailable by 1980, and pregnancy from 1980 onward is likely
o reflect the modern era of medical management of LQTS.
he nulliparous group contained women who had reached
ge 41 years and completed the defined childbearing period
ithout giving birth or women who were younger than age
1 and had not yet had a child before March 2003.
The childbearing age range involved women ages 15
hrough 40. The LQTS Registry was accessed in October
005 for the required data, thus providing a minimum of 30
onths of follow-up information after March 2003. Data
egarding cardiac events, beta-blocker usage, genotype data,
nd birth dates of children were collected. If the studied
regnancies occurred before the subject was enrolled in the
egistry, information was obtained retrospectively from the
atient or from medical records.
isk and outcome events. To evaluate the cardiac risk
ssociated with pregnancy, peripartum time periods imme-
iately before, during, and after pregnancy were divided into
qual 9-month time intervals. The pregnancy interval was
efined as the 9-month interval before the date of delivery.
he estimated date of conception was defined as the first
ay of the pregnancy interval. The 9-month interval before
he estimated date of conception was defined as the prepreg-
ancy time interval. The postpartum interval was defined as
he 9-month interval after the child’s birth. The post-
ostpartum interval represents the time after the postpartum
nterval until the date of last follow-up or age 41, excluding
he peripartum time periods of subsequent pregnancies. If a
oman had more than 1 child, each time period for each
regnancy was analyzed. If 2 of the described time periods
verlapped in a woman’s history, both time periods were
ensored as previously described (4). Stillbirths, spontane- bus abortions, and elective abor-
ions were excluded from the
nalysis because the length of
regnancy was not available.
Outcome variables included
QTS-related death, aborted
ardiac arrest, and syncope. Un-
xpected, sudden death without a
nown cause before age 41 was
ategorized as LQTS-related death (1). Aborted cardiac
rrest was defined as cardiac arrest that was terminated by
lectrical cardioversion. Syncope was defined as transient
oss of consciousness with abrupt onset and offset.
enotype data. Standard genetic tests for LQTS muta-
ions were performed in academic molecular-genetic labo-
atories associated with the registry. Among women in the
tudy population with an LQTS-related mutation, only
ubjects with LQT1 (n 82 from 53 families), LQT2 (n
9 from 43 families), and LQT3 (n  12 from 8 families)
enotypes were identified. The remainder of the study
opulation with QTc 470 who did not have an LQTS-
elated mutation identified or did not have genetic testing
erformed were categorized as nongenotyped.
tatistical analyses. The probability of cardiac events was
valuated using the method of Kaplan and Meier with the
og-rank statistic. The Cox proportional-hazards survivorship
odel (8) with allowance for time-dependent covariates (SAS
ersion 9.1.3, SAS Institute Inc., Cary, North Carolina) was
sed to evaluate the independent risk of the peripartum time
eriods in predicting cardiac event end points among LQTS
omen from ages 15 through 40. In the analyses related to the
nd point, any cardiac event (syncope, ACA, or LQTS-related
eath), QTc, and the presence of any cardiac event before age
5 (syncope or ACA) were included as covariates in the Cox
odel. In the analyses related to life-threatening events (ACA
r LQTS-related death), QTc and time-dependent interim
yncope stratified by the time interval before the lethal event
2 years, 2 years) were included as covariates in the Cox
ode. The efficacy of beta-blocker therapy was evaluated as a
ime-dependent covariate in the Cox model. The SAS proce-
ure PROC PHREG was used—it allows specification of
ime-dependent covariates by using a data-related step-like
rogramming code that compares the timing of the time-
ependent covariate with the survival time of the end point (9).
lease see the Appendix for further details of the statistical
nalysis and an example of the programming code.
esults
ntire cohort. CLINICAL CHARACTERISTICS OF LQTS
OMEN. The clinical characteristics of women who did not
ave a birth and women who had a live birth both before
980 and from 1980 to 2003 are presented in Table 1. The
ulliparous women had a shorter average follow-up time, a
igher event rate before age 15, and a higher use of
Abbreviations
and Acronyms
ACA  aborted cardiac
arrest
CI  confidence interval
ECG  electrocardiogram
LQTS  long QT syndromeeta-blockers at age 15 than the 2 live-birth groups.
Ld
s
h
w
M
p
t
t
(
T
i
c
t
f
b
b
a
c
w
y
A
1
a
r
h
h
T
4
m
m
d
r
t
R
I
s
r
t
oracic s
1094 Seth et al. JACC Vol. 49, No. 10, 2007
LQTS and Pregnancy March 13, 2007:1092–8IVE BIRTH AND CARDIAC EVENTS. Time-dependent car-
iac event data for women between ages 15 and 40 are
hown in Figure 1. Nulliparous women had a somewhat
igher probability of experiencing a cardiac event than those
ho had a live birth before 1980 or from 1980 to 2003.
odern pregnancy cohort. To describe the effects of
regnancy on the clinical course of women with LQTS in
he modern era, the remainder of the article will involve only
hose women who had a live birth from 1980 to 2003
modern cohort, n  391).
Clinical Characteristics of LQTS Women in the Nand in Those Who Had a Live Birth Before 1980
Table 1 Clinical Characteristics of LQTS Woand in Those Who Had a Live Birth
Variable
Nullip
(n
QTc, ms 50
Heart rate, beats/min 7
Cardiac event before age 15 yrs, %
Cardiac event after age 15 yrs, %
Number of cardiac events after age 15 yrs 2
Death, %
Follow-up time age 15–40 yrs 12
Survival time age 15 to first cardiac event, yrs 8
Time from age 15 to first live birth, yrs
Genotype, %
LQT1
LQT2
LQT3
Unknown
Therapy, %
Beta-blocker use at age 15 yrs
ICD before age 15 yrs
LCTSG surgery before age 15 yrs
Pacemaker before age 15 yrs
Plus-minus values indicate mean  SD.
ICD  implantable cardioverter-defibrillator; LCTSG  left cervicoth
Figure 1 Kaplan-Meier Curves
Kaplan-Meier curves for the cumulative probability of a first cardiac event from
age 15 through age 40 in women who were nulliparous without a live birth,
those who had a live birth before 1980, and those who had a live birth
between 1980 and 2003.pIMING OF CARDIAC EVENTS. Figure 2 shows the annual-
zed cardiac event rate by time period for the modern
ohort. The time periods include all times from ages 15
hrough 40. The pre-pre-first pregnancy period is the time
rom age 15 to the first prepregnancy period, the 9 months
efore the woman’s first pregnancy. In the case of multiple
irths, subsequent prepregnancy time periods were not
nalyzed because of a significant amount of overlapping and
ensoring of time periods. The annualized cardiac event rate
as higher in the 9-month postpartum period (0.23 events/
ear) than in the other defined peripartum time periods.
borted cardiac arrest and LQTS-related death account for
7% of the annualized events in the postpartum period. The
nnualized event rates for nonpostpartum time periods
anged from 0.04 to 0.09 events/year. Of note, no woman
ad her first cardiac event on the day of or within 1 day of
er first live-birth delivery.
HE POSTPARTUM PERIOD. The cardiac event rate for the
-year period after conception among LQTS women in the
odern cohort is shown in Figure 3. The graph shows a
eaningful increase in the probability of a first cardiac event
uring the first 6 months after childbirth, with a somewhat
educed increase in the probability of a first cardiac event
hereafter.
ISK OF CARDIAC EVENT BY PERIPARTUM TIME PERIODS.
n the Cox proportional-hazards survivorship analyses
hown in Table 2, the hazard ratios were calculated using a
eference comparison time period from age 15 to the start of
he woman’s first pregnancy period. The pregnancy time
arous Grouprom 1980 to 2003
in the Nulliparous Group
e 1980 or From 1980 to 2003
Group
0)
Live Birth <1980
(n  173)
Live Birth >1980
(n  391)
0 490 50 500 50
9 70 15 72 16
18 28
49 55
1 2.6 8.7 2.7 8.2
9.2 4.3
.2 24.2 4.7 20.3 6.3
.9 16.7 10.2 13.3 9.0
8.4 11.0
23 21
11 15
2 3
64 61
2 9
0 0
0 1
0 2
tellate ganglionectomy; LQTS  long QT syndrome.ullipor F
men
Befor
arous
 52
0 6
3 1
38
55
.6 1
7.4
.8 8
.5 7
10
10
2
78
25
1
2
4eriod had a reduced risk for any cardiac event (hazard ratio
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March 13, 2007:1092–8 LQTS and Pregnancy.28, 95% confidence interval [CI] 0.10 to 0.76, p  0.01),
hereas the postpartum period was associated with an
ncreased risk for cardiac events (hazard ratio 2.7, 95% CI
.8 to 4.3, p  0.001). The post-postpartum period had a
isk similar to or lower than that associated with the first
repregnancy interval. As shown in Figure 4, the high rate
f postpartum events was dominated by women with the
QT2 genotype. The LQT3 women seemed to have a
omewhat different distribution of event rates in the various
eripartum time periods, but the number of LQT3 women
Figure 2 Annualized Cardiac Event Rates
Annualized cardiac event rates (syncope and aborted cardiac arrest [ACA]/long QT
pregnancy-related time periods for 391 women who had a live birth between 1980
Figure 3 Cumulative Probability
Cumulative probability of a first cardiac event during 48 months after first concep-
tion after age 15 in the 391 women who had a live birth between 1980 and 2003. ss too small to compare peripartum event rates between
QT3 and the other 2 genotype groups. The post-
ostpartum period was associated with a low annualized
vent rate in all 4 groups, and this low rate is similar to or
ower than that associated with the first prepregnancy
nterval. Using Kaplan-Meier survival analysis to compare
he cumulative probability of cardiac events in genotyped
omen who had a live birth, those with the LQT2 genotype
ere more likely (p  0.003) to experience a cardiac event
han women with the LQT1 genotype, although the QTc
uration was similar in the 2 genotypes (data not shown).
ome [LQTS]-related death) for defined
003. See text for definitions of time periods.
he Hazard Ratios for Any Cardiac Event and Life-reatening Events (Aborted Cardiac Arrest orQTS-Related Death) in th P egnancy, Postpartum,nd Post-Postpar um Time Periods for 391 Wom nith Live Bir hs Between 1980 nd 2003
Table 2
The Hazard Ratios for Any Cardiac Event and Life-
Threatening Events (Aborted Cardiac Arrest or
LQTS-Related Death) in the Pregnancy, Postpartum,
and Post-Postpartum Time Periods for 391 Women
With Live Births Between 1980 and 2003
Time Period
Any Cardiac Event
(n  214 of 391)
Life-Threatening Event
(n  55 of 391)
Hazard Ratio
(95% CI) p Value
Hazard Ratio
(95% CI) p Value
Pregnancy 0.28 (0.10–0.76) 0.01 1.5 (0.49–4.5) 0.49
Postpartum 2.7 (1.8–4.3) 0.001 4.1 (1.7–9.5) 0.001
Post-postpartum 0.91 (0.55–1.5) 0.70 1.9 (0.84–4.1) 0.13
he reference for the hazard ratios is each woman’s time from age 15 to the start of her first
regnancy. The hazard ratios for Any Cardiac Event are adjusted for QTc and cardiac events before
ge 15. The hazard ratios for Life-Threatening Events are adjusted for QTc and time-dependentsyndr
and 2yncope stratified by time before the lethal event.
CI  confidence interval; other abbreviations as in Table 1.
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LQTS and Pregnancy March 13, 2007:1092–8To better understand the risk of life-threatening events,
he more serious events, ACA or LQTS-related death, were
nalyzed separately from syncope (Table 2). The risk for
borted cardiac arrest or LQTS-related death, whichever
ccurred first, was increased in the postpartum period (p 
.001), but the pregnancy and post-postpartum time periods
ere not associated with a significantly increased risk for
ife-threatening events.
FFECT OF BETA-BLOCKER THERAPY. Of the 391 women of
he modern cohort, 104 were using beta-blockers at conception
27%), 116 at the time of childbirth (30%), and 128 at 9
onths after giving birth (33%). Ninety percent of women
ho were using beta-blockers remained on the medication
hroughout these time points. In Figure 5, the effect of
eta-blocker use by pregnancy time period is shown by com-
aring the annualized cardiac event rates of those who used
eta-blockers with those who did not. Beta-blockers were
ssociated with a reduction in annualized cardiac event rate
uring the high-risk postpartum time period, with an annual-
zed event rate of 3.7 events/year in the absence of beta-
lockers and 0.8 events/year with beta-blockers. In a Cox
roportional-hazards survivorship analysis (Table 3), time-
ependent beta-blocker use was associated with a significant
eduction in cardiac events only in the postpartum period
hazard ratio 0.34, 95% CI 0.14 to 0.84, p  0.02). A
ignificant beta-blocker effect was not seen for life-threatening
Figure 4 Annualized Cardiac Event Rates
Annualized cardiac event rates (syncope, aborted cardiac arrest, or long QT syndro
for defined pregnancy-related time periods for 391 women who had a live birth. Novents (hazard ratio 0.65, p  0.60), with the lack of signifi- tance possibly caused by limited power, with only 15 life-
hreatening events in this secondary analysis.
iscussion
ur findings indicate that among women with LQTS who
ave birth, the 9-month postpartum time is associated with a
.7-fold increased risk of experiencing a cardiac event and a
.1-fold increased risk of experiencing a life-threatening event
hen compared with the preconception time period. After this
ransient high-risk postpartum period, the risk of cardiac
vents reverts to the baseline prepregnancy risk. The pregnancy
eriod is associated with a reduced risk for cardiac events. The
ncreased risk for cardiac events in the postpartum period was
ignificantly reduced by beta-blockers. Furthermore, women
ith the LQT2 genotype are at a considerably higher risk for
ardiac events during the postpartum period than those with
QT1 or LQT3 genotypes.
This study adds to the existing information on LQTS
nd pregnancy (4–6). With our larger population, we have
tudied the entire childbearing period from age 15 to 40
ears and more precisely identified the postpartum risk for
ny cardiac event (mostly syncope), and also for life-
hreatening cardiac events (aborted cardiac arrest and
QTS-related sudden death). The benefit from beta-
locker therapy, especially in reducing the postpartum risk,
s now well documented. Our findings confirm and extend
QTS] death) by genotype (LQT1, LQT2, LQT3, nongenotyped)
the 12 LQT3 women had a cardiac event during the post-postpartum period.me [L
ne ofhe report of Khositseth et al. (5), who identified the
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March 13, 2007:1092–8 LQTS and Pregnancyarticularly high postpartum cardiac risk in 14 women with
he LQT2 genotype, and the recent report of Heradien et al.
6), who showed a low rate of cardiac events during
regnancy in 36 women with a specific LQT1 genotype.
The overall lower risk of experiencing a cardiac event among
hose who gave birth as contrasted with the women who were
ulliparous may be attributable to several factors. Pregnancy
rings women to health care providers, and this may be a factor
ontributing to more effective preventive management during
regnancy. Importantly, there may be a self-selection bias
egarding pregnancy in our LQTS study population. Our
nalysis shows that although the nulliparous women did not
ave a longer QTc interval than those who gave birth, they did
ave more cardiac events before age 15 and more of them were
sing beta-blockers by age 15. These women may have chosen
Figure 5 Annualized Cardiac Event Rates
Annualized cardiac event rates by beta-blocker use in the pregnancy, postpartum,
and 2003. Beta-blockers were associated with a significant reduction (p  0.01) i
text for details.
he Hazard Ratios for Any Cardiac Event for Time-ependent Beta-Blocker Use During the Pregnancy,ostp rtum, nd P st-Postp t m Time Periods for91 Women With Live Births Between 1980nd 2003
Table 3
The Hazard Ratios for Any Cardiac Event for Time-
Dependent Beta-Blocker Use During the Pregnancy,
Postpartum, and Post-Postpartum Time Periods for
391 Women With Live Births Between 1980
and 2003
Time Period
Any Cardiac Event
Hazard Ratio
(95% CI) p Value
Time-dependent beta-blocker use
Pregnancy 0.16 (0.02–1.3) 0.08
Postpartum 0.34 (0.14–0.84) 0.02
Post-postpartum 0.52 (0.14–1.9) 0.32r
he hazard ratios are adjusted for QTc and cardiac events before age 15.
CI  confidence interval.ot to become pregnant for this reason. Unfortunately, we are
nable to adjust for this potential bias.
The postpartum interval was a particularly high-risk
eriod. There are several influences that may be contribut-
ng to this phenomenon. Biologically, there are many
nique physiological changes occurring during the postpar-
um period. Cardiac remodeling and increasing cardiac
utput are gradual processes during pregnancy, but in the
ostpartum period the decline in cardiac output is rapid,
ith cardiac output decreasing 37% from 8.8 to 5.4 l/min
10). Recently, Mone et al. (11) found normal pregnancy to
e associated with a reversible decrease in myocardial
ontractility. They noted that systolic function is preserved
hroughout most of pregnancy by a decrease in afterload,
ith reduction in contractility and preload in the early
ostpartum period. These changes in hemodynamics in the
ostpartum period may be a contributing factor to cardiac
rrhythmias and the increased postpartum cardiac event rate
xperienced by women with LQTS.
Rashba et al. (4) hypothesized that alterations in adrenergic
ctivity in the peripartum period may cause an increase in
ostpartum cardiac events. It may be that the increase in
ympathetic activity that occurs with the stress and disrupted
leep pattern when caring for a newborn is a factor that triggers
alignant tachyarrhythmias in patients with LQT1 and
QT2 genotypes, as hypothesized by Schwartz et al. (12). In
he current study, the risk was particularly accentuated in the
QT2 genotype, and this finding is in alignment with the
st-postpartum time periods for 391 women who had a live birth between 1980
nnualized cardiac event rate during the high-risk postpartum time period. Seeand po
n the aecent report by Khositseth et al. (5). Interestingly, the LQT3
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LQTS and Pregnancy March 13, 2007:1092–8omen had a higher annualized event rate during pregnancy
han in the postpartum period, but this finding is difficult to
nterpret because there were only 12 women with the LQT3
enotype who had live births.
Estrogen and progesterone levels are high during pregnancy
nd decrease well below normal levels when the mother
reastfeeds her child. The profound decrease in estrogen and
rogesterone levels after delivery seems to be the initiating
timulus for lactation. This alteration in hormone levels could
nfluence the adrenergic responses of the mutant ion channels
n LQTS. Animal studies have provided several interesting
ndings. Protein expression of cardiac beta-1–adrenergic re-
eptors have been shown to be downregulated in the presence
f estrogen in ovariectomized animals (13). In animal studies,
strogen has weak antiarrhythmic effects and it may reduce the
isk of the polymorphic ventricular antiarrhythmia (torsades de
ointes) in LQTS patients (14). Therefore, deprivation of
strogen, such as that seen in the breastfeeding state, may
ncrease adrenergic activity and cardiac myocyte excitability in
he postpartum period and contribute to a higher probability of
dverse cardiac events. Similarly, the hyperestrogenic state
uring pregnancy may be a factor associated with a reduced risk
f cardiac events during this time period.
The increased risk of cardiac events during the postpar-
um period was significantly reduced among women using
eta-blocker therapy. Beta-blockers are transmitted in the
ilk to the nursing infant, and although they can reduce the
eart rate to some degree in the nursing infant, the benefit
o the mother far outweighs the negligible risk to the
ursing infant. We recommend that beta-blockers be pre-
cribed to women with LQTS, with our findings most
trongly documenting the benefit in the high-risk postpar-
um period that is dominated by the LQT2 genotype.
tudy limitations. Potential recall bias is a concern. Study
ubjects may have recalled more cardiac events during the
ostpartum time period because of their concerns about
heir newborn infant. We only have 1 ECG recording on
ost women, so we do not have reliable data on the change
n the QTc before, during, and after pregnancy. Unreported
eta-blocker discontinuation may have occurred during
imes of pregnancy and lactation because of apprehension
bout taking medications during these time periods. In the
nalyses, beta-blocker therapy was modeled as a time-
ependent covariate. This means that at each point in time
age), those on beta-blockers were compared with those not
n beta-blockers within each covariate pattern. We know
hether the subjects were prescribed beta-blockers, but we
annot be certain whether they actually took the beta-
locker on any given day. Thus, the reported efficacy of peta-blockers may be an underrepresentation of the true
fficacy of this therapy.
onclusions
he 9-month postpartum period is associated with a sig-
ificantly increased risk of experiencing a cardiac event,
specially in subjects with the LQT2 genotype. Beta-
locker use was associated with a reduction in cardiac events
uring the high-risk postpartum time period.
eprint requests and correspondence: Dr. Arthur J. Moss, Heart
esearch Follow-up Program Box 653, University of Rochester
edical Center, Rochester, New York 14642. E-mail: heartajm@
eart.rochester.edu.
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APPENDIX
or an example of the programming code used in the statistical analyses,
lease see the online version of this article.
